Results 241 to 250 of about 145,978 (310)

Monitoring Extended Half‐Life Factor VIII and IX Concentrates: Performance in Routine Clotting‐and Thrombin Generation Assays

Haemophilia, EarlyView.
ABSTRACT Introduction Monitoring extended half‐life (EHL) factor (F) VIII and FIX products is complex, as discrepant results are obtained in different laboratory assays. Aim To provide an overview on assay accuracy based on a re‐assessment of previously published data as well as laboratory results of EHL spiking experiments for specific factor assays ...
An K. Stroobants, Eva‐Leonne Göttgens, Yvonne M. C. Henskens, Joop H. Jansen, Saskia E. M. Schols, Sanna R. Rijpma   +5 more
wiley   +1 more source

Fitusiran treatment modulates the ratio between alpha- and beta-antithrombin isoforms. [PDF]

Hemasphere
McCluskey G, Maynadié H, Borgel D, Frenzel L, Harroche A, Bianchini E, Roullet S, Christophe OD, Denis CV, Casari C, Lenting PJ.   +10 more
europepmc   +1 more source

Seventh Åland Island Meeting on von Willebrand Disease

Haemophilia, EarlyView.
ABSTRACT Introduction The seventh Åland Island Meeting on von Willebrand Disease (VWD) was held on the Åland archipelago in Finland, from 26 to 28 September 2024. Aim The meeting brought together experts in the field of VWD from around the world to share the latest advances and knowledge in VWD.
Riitta Lassila, Ruben Bierings, Nathan T. Connell, Fernando F. Corrales‐Medina, Augusto B. Federici, Veronica H. Flood, Floor Heubel‐Moenen, Jill M. Johnsen, Geoffrey Kuppens, Davide Matino, Carolyn Millar, Ingmar Schoen, Anish Sharda, Robert F. Sidonio Jr, Alok Srivastava, Timea Szanto, Angela C. Weyand, Erik Berntorp   +17 more
wiley   +1 more source

Aβ₁₋₄₀ Enhances Platelet Sensitivity to Thrombin via NADPH Oxidase-ROS Signaling and Integrin α_IIbβ_₃ Engagement. [PDF]

Biomol Ther (Seoul)
Kim B, Lee BK, Kim JA, Jung YS.
europepmc   +1 more source

Procoagulant Effect of FIX Concentrates and Bypass Agents in Combination with Emicizumab and Impact of FVIII Inhibitors. [PDF]

Biomedicines
Arias-Salgado EG, Álvarez Román MT, Dos Santos Ortas A, Fernandéz-Bello I, Monzón Manzano E, Acuña P, Martín Salces M, Rivas Pollmar MI, García Barcenilla S, Butta NV, Jimenéz-Yuste V.   +10 more
europepmc   +1 more source

Perioperative Outcomes in Factor XI Deficiency: A Systematic Review

Haemophilia, EarlyView.
ABSTRACT Background Congenital factor XI (FXI) deficiency has a variable bleeding phenotype, and FXI activity alone does not predict perioperative bleeding. Management practices remain heterogeneous, and available evidence derives from case reports, small case series, and retrospective cohorts.
Zainab Al‐Housni, Raeesah Mohammed, Silvio Ligia, Jim Douketis, Chatree Chai‐Adisaksopha, Alfonso Iorio, Davide Matino   +6 more
wiley   +1 more source

High-Affinity Six-Letter DNA XenoAptamer Generation by Genetic Alphabet Expansion. [PDF]

J Am Chem Soc
Matsunaga KI, Tan HP, Low JL, Kimoto M, Hirao I.   +4 more
europepmc   +1 more source

An Ex Vivo Pharmacodynamic Study of KN057, a Tissue Factor Pathway Inhibitor Neutralizing Antibody, in Plasma Samples From Patients With Haemophilia or VWD3

Haemophilia, EarlyView.
ABSTRACT Introduction Tissue factor pathway inhibitor (TFPI), a key regulator of tissue factor‐initiated coagulation through FXa‐dependent inhibition of the tissue factor‐FVIIa complex, has emerged as a promising target for restoring thrombin generation.
Mankai Ju, Feng Xue, Wei Sun, Fang Li, Ting Xu, Renchi Yang   +5 more
wiley   +1 more source

Targeting PAR1 biased signaling with parmodulin reduces thromboinflammation and acute lung injury in sickle cell disease. [PDF]

Blood Adv
Ramadas N, Lowder K, Dutton J, Kazen RC, Sellers R, DeRousse JT, Dockendorff C, Sparkenbaugh EM.   +7 more
europepmc   +1 more source

Thrombin [PDF]

, 2017
openaire   +1 more source